by Market Overview:
Adoptive cell therapy is an advanced form of immunotherapy that involves providing specific immune cells to treat cancer and other diseases. It involves removing immune cells from a patient’s blood or tumor and expanding them outside the patient’s body before re-administering them to help the immune system fight the disease. Adoptive cell therapy has advantages over traditional treatment methods as it provides personalized and targeted therapy with minimal side effects.
Market key trends:
Increasing adoption rates of adoptive cell therapy for cancer treatment is expected to significantly drive the market growth over the forecast period. This is attributed to the rising preference for personalized medicine and cell therapies among oncologists. Additionally, continuous technological advancements in adoptive cell therapy such as the development of CAR T-cell therapies for solid tumors is further expected to fuel the market expansion. Patent expirations of key immuno-oncology drugs is another factor likely to open lucrative opportunities for the market players to develop novel adoptive cell therapy products.
Segment Analysis
The global adoptive cell therapy market is segmented based on therapy, indication, end-user, and region. Based on therapy, the market is segmented into tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. The CAR T cell therapy segment dominated the market in 2022 due to successful FDA approvals and commercialization of CAR T cell therapies such as Kymriah and Yescarta for certain cancers.
Key Takeaways
The global Adoptive Cell Therapy Market Demand is expected to witness high growth, exhibiting a CAGR of 21.5% over the forecast period of 2023-2030, due to increasing prevalence of cancer globally and advancements in immunotherapy. Regionally, North America is expected to dominate the market during the forecast period attributed to growing research activities for adoptive cell therapies and presence of key market players in the region. Key players operating in the adoptive cell therapy market are Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs.
The global adoptive cell therapy market size was valued at US$ 4,932.5 million in 2022. The market is primarily driven by rising cancer prevalence across the world. According to the World Health Organization (WHO), cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020. Adoptive cell therapy provides an effective treatment approach for cancer management.
Regionally, North America dominated the global adoptive cell therapy market in 2022 and is expected to retain its lead over the forecast period. The growth can be attributed to robust research funding schemes for developing advanced cancer therapies, establishment of Centers of Excellence across the US and Canada, and presence of key market players. For instance, the National Cancer Institute allocated US$ 6.2 billion funds for cancer research in 2022.
Key players operating in the adoptive cell therapy market adopt product approvals, partnerships, and new product launches as strategies to strengthen their market position. For instance, in September 2022, Lineage Cell Therapeutics received FDA approval for its OpRegen therapy for the treatment of dry age-related macular degeneration. In August 2022, Sana Biotechnology entered into a partnership with CRISPR Therapeutics to develop in vivo gene-editing therapies.
Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
